Stockscreener 앱 받기
6.03
2.11%
-0.13
시간 외 거래:
6.09
0.06
+1.00%
Turn Therapeutics Inc 주식(TTRX)의 최신 뉴스
Number of shareholders of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Slight EPS Miss Amid Pre-Revenue Stage; Shares Rise - newsline.com
TTRX Q1 2026 Earnings: Narrow EPS Miss Highlights Ongoing Development PhaseRevenue Miss Report - newsline.com
TTRX Q1 2026 Earnings: Slight EPS Miss as Company Reports Loss Per Share of -$0.026Quarterly Profit Report - newsline.com
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down - Yahoo Finance
TTRX Q1 2026 Earnings: EPS Misses Estimates, Shares Fall 4.6%Profit Margin Analysis - newsline.com
2 Software Stocks to Keep an Eye On and 1 We Turn Down - Yahoo Finance
2 Financials Stocks to Target This Week and 1 We Turn Down - Yahoo Finance
TTRX: GX-03 shows rapid, biologic-level efficacy and safety in eczema, with broad expansion plans - TradingView
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data - TipRanks
Turn Therapeutics posts positive GX-03 Phase 2 interim results, updates investor presentation - TradingView
Turn Therapeutics (NASDAQ: TTRX) details GX-03 interim data, onychomycosis plans and runway - Stock Titan
Turn Therapeutics reports interim phase 2 data for eczema drug By Investing.com - Investing.com Australia
Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch - RTTNews
Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results - Moomoo
Phase II bid Turns out safe, EASI, effective; AD topical island? - BioWorld News
Turn Therapeutics reports interim phase 2 data for eczema drug - Investing.com UK
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data - TipRanks
Turn Therapeutics’ GX-03 Shows Rapid and Significant Efficacy in Phase 2 Atopic Dermatitis Trial with Strong Safety Profile 123 - Minichart
Turn Therapeutics interim Phase 2 analysis shows rapid, deep EASI responses and favorable safety for GX-03 - TradingView
Turn Therapeutics reports interim analysis findings and adaptive optimization strategy from phase 2 GX-03 trial in moderate-to-severe atopic dermatitis - marketscreener.com
Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis - TradingView
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - The Joplin Globe
Turn Therapeutics publishes GX-03 dermatitis study results - Investing.com UK
Turn Therapeutics highlights GX-03 preclinical data in dermatitis - TipRanks
Turn Therapeutics publishes GX-03 dermatitis study results By Investing.com - Investing.com Australia
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model - Business Wire
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Narrow EPS Miss Overshadowed by Operational ProgressReturn On Assets - thelegaladvocate.com
TTRX Q1 2026 Earnings: Narrow Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances Pipeline - Newser
Turn Therapeutics (TTRX) Q1 2026 Earnings: Narrow EPS Miss Amid Modest Stock GainsProfit Guidance Range - Newser
Turn Therapeutics (TTRX) Stock Trend: +2.10% Higher, $5.11 the Next Hurdle 2026-05-21Pro Trader Picks - Newser
Turn Therapeutics to Present GX-03 Atopic Dermatitis Therapy Updates at Jefferies Global Healthcare Conference 2026 12 - Minichart
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - PharmiWeb.com
Turn Therapeutics CEO to Present at Jefferies Conference - TipRanks
Turn Therapeutics to Present at Jefferies Global Healthcare Conference June 4 - TradingView
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn to Lead Clinical and Regulatory Strategy for GX-03 Atopic Dermatitis Therapy 1 - Minichart
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03 - TipRanks
Turn Therapeutics Recruits Former FDA Commissioner Stephen Hahn to Guide Eczema Drug Development - citybiz
Turn Therapeutics appoints former FDA chief Stephen Hahn - Investing.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - Weekly Voice
Turn Therapeutics appoints former FDA chief Stephen Hahn By Investing.com - Investing.com Canada
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Turn Therapeutics (TTRX) Stock: Up +1.25%, Key Resistance at $4.26 2026-05-14Mid Cap Momentum - newser.com
Turn Therapeutics (Direct Listing) (TTRX) Earnings Calendar_Earnings Analysis_Financial Report and Earnings Call - Tiger Brokers
Turn Therapeutics Reports First Quarter 2026 Financial Results - TradingView
Turn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - standard-journal.com
The key trends fueling Turn Therapeutics (TTRX) growth potential (-2.37%) 2026-05-11Elite Trading Signals - newser.com
2.60%
0.94%
자본화:
|
볼륨(24시간):